Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its first M&A deal under the new helmsman, a securities filing shows.